Programme (for Session 4, see • World TB Day Symposium... ))
Welcome: Professor Marc Lipman (Director, UCL-TB director)
03:49 Introductory remarks
04:04 Professor Ibrahim Abubakar (Dean of the UCL Faculty of Population Sciences)
08:43 Professor Liam Smeeth (Director, LSHTM)
12:18 Session 1 - Health consequences following tuberculosis
Microbiological cure of TB is not always the end of disease for many patients. A significant proportion will suffer with complications of damage caused to the lungs and other organs post-TB. This session will examine the challenges and consequences of post-TB sequelae across disciplines. Presentations and discussion will highlight the key health and economic consequences following TB and upcoming research priorities, including the re-prioritisation of screening interventions and potential therapy to prevent post-TB pathological damage.
Chairs - Professor Katharina Kranzer (LSHTM) / Professor Marc Lipman (UCL)
12:53 Former TB Patient/Advocate: Patient experience of life after TB treatment - Recorded interview (This interview has been removed from the recording for privacy reasons)
13:44 Dr Matt Quaife (LSHTM) Health and economic costs of post-TB sequelae
25:05 Dr Gabriele Pollara (UCL) Rational strategies for host-directed therapy to minimize post-TB lung damage
39:19 Dr Toyin Togun (LSHTM) Post-TB lung health in children in West Africa
44:50 Panel discussion
1:02:15 Session 2 - Understanding Mycobacterium tuberculosis in the post- genomic era
Why is M. tuberculosis the world’s ‘most successful pathogen’? What parts of its known and unknown biology contribute to this reputation? In 1998, Stewart Cole et al. used Whole Genome Sequencing to paint a picture of an organism with unusual metabolism encoding 100’s of genes of unknown function. This has since been followed up with various Next Generation Sequencing applications revealing unique characteristics concerning evolution of drug resistance, resistance evasion and gene expression control. This session aims to showcase M. tuberculosis as an exceptional organism as well as a pathogen and how new techniques can bring fresh insight into disease treatments and control.
Chairs - Dr Isobella Honeyborne (UCL) / Dr Sam Willcocks (LSHTM)
1:02:42 Professor Tim McHugh (UCL) Post-genomic TB research and its role in diagnostics and drugs
1:17:58 Dr Gwen Knight (LSHTM) How mathematical models can be used to understand emergence of drug resistance in tuberculosis
1:28:05 Dr Dimitrios Evangelopoulos (UCL) What drives resistance evasion in TB: lessons from cycloserine
1:40:52 Dr Terry Kipkorir (UCL) Riboswitches, sensing and adapting to host environment via RNA through co- and post-transcriptional regulation
1:53:29 Panel discussion
2:09:31 Breaking news
Chair - Professor Beate Kampmann (LSHTM)
Dr Anna Turkova (UCL) SHINE trial and WHO paediatric TB guidance update
2:21:20 Discussion
2:25:16 Session 3 - The impact of COVID-19 on TB
The COVID-19 pandemic caused substantial disruption to health services and affected health seeking behaviour. TB notifications have reduced globally representing a significant setback for TB control. This session begins with a high-level overview of the impact of COVID-19 on TB prevention, diagnosis, care and treatment and solutions going forward. Following this, data on TB notifications before and after March 2020, from a range of settings, will be presented and interpreted followed by lessons learned going forwards. The modelled impact of COVID-19 on BCG vaccination uptake, and its implication for paediatric TB mortality, will be presented. And the implications of co-infection with COVID-19 for the accuracy of TB diagnosis will be explored using data from a 4-country cohort study.
Chairs - Professor Beate Kampmann (LSHTM) / Professor Francois Balloux (UCL)
2:25:56 Dr Rachael Burke (LSHTM / MLW) Effect of COVID on TB notification in Peru, South Africa and Malawi
2:36:30 Ms Nabila Shaikh (LSHTM) Impact of COVID-19 on global BCG coverage and paediatric tuberculosis mortality
2:48:20 Dr Jayne Sutherland (LSHTM/MRC Gambia) Influence of current and recent COVID on performance of novel TB diagnostics (This presentation has been removed from the recording at the request of the presenter)
2:49:10 Panel Discussion
Handover to UCSF
3:01:04 Dr Finn McQuaid (LSHTM) London closing remarks and switch to UCSF (link TBC)
Session 4 - Joint session on clinical trials with UCSF (The recording of this session has been uploaded separately, and is available at • World TB Day Symposium... )
For more about UCL-TB, see www.ucl.ac.uk/tb/
Негізгі бет World TB Day Symposium 2022 sessions 1-3
Пікірлер